At least three states have recently introduced bills to require transparency surrounding the cost and pricing of diabetes medicines, posing a growing challenge to the pharmaceutical industry.
Over the past few weeks, legislation was introduced in South Carolina, Hawaii, and Colorado, and the intent of each bill largely mirrors a controversial law that was adopted last fall by Nevada, which is now fending off a lawsuit filed by the industry’s largest trade group.
The efforts underscore an uphill battle facing drug makers. Although other state lawmakers have pursued so-called transparency laws designed to dampen price hikes, Nevada gained widespread notice because it became the first state to target medicines for a specific ailment.
About the Author Reprints
